Repeated administration of low-dose topotecan leads to DNA damage and induced senescence in both MYCN-amplified neuroblastoma cells and in vivo in neuroblastoma xenografts, together with tumor regression [22]. The gene discussed is MYCN; the disease is neuroblastoma.